BTK and myeloid sarcoma: BTK inhibitors that are currently being investigated in MS phase III clinical trials include evobrutinib, tolebrutinib and fenebrutinib, each with distinct pharmacological profiles that differ in potency, selectivity and CNS distribution (Supplementary Table 1) [173].